Refine your search:
You can use: AND, NOT, OR, " " (exact phrase)
Search across all Transcripts:
You can use: AND, NOT, OR, " " (exact phrase)
-
... becoming a leading bio-pharmaceutical company. And given Nexavar’s continued sales growth, encouraging new clinical ... of having tremendous investor interest in developing Nexavar multiple settings. And there were more than ...
-
... Phase II investigator initiated combination studies. Nexavar revolutionized the treatment landscape for two ... advanced thyroid cancer patients treated with Nexavar, demonstrated a significantly longer, medium progression ...
-
... pivotal lung cancer setting, Nexus, is evaluating Nexavar in combination with gemcitabine and cisplatin versus ... we have initiated signal generating trial evaluating Nexavar maintenance therapy for ovarian cancer patients ...
-
... expenses across quarters. Total shared Nexavar sales and marketing expenses incurred ... have a significant percentage of Nexavar commercial and development expenses outside ... drugs has to open up. Nexavar to be added to that ...
-
... from a randomized discontinuation trial demonstrating that Nexavar improved progression-free survival in patients who ... the liver cancer indication. Total shared Nexavar development expenses under the collaboration were $ ...
-
... can move forward opportunistically as appropriate. While Nexavar remains the cornerstone of business and the ... lung cancer study sponsored by ECOG administering Nexavar as monotherapy. Incremental information on sub-groups ...
-
... These previously untreated patients received Nexavar or placebo in combination with ... HER2-negative metastatic breast cancer, comparing Nexavar to placebo in combination with ... a lot of familiarity with Nexavar if he or she is ...
-
... independent data monitoring committee found that Nexavar significantly improved overall survival, progression-free survival ... Despite the increasingly competitive marketplace, Nexavar continues to play a significant role ...